Compare · AGMB vs GILD
AGMB vs GILD
Side-by-side comparison of AgomAb Therapeutics NV (AGMB) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AGMB and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $160.55B, about 260.6x AGMB ($616.1M).
- Over the past year, AGMB is down 16.7% and GILD is up 14.5% - GILD leads by 31.1 points.
- GILD has been more active in the news (6 items in the past 4 weeks vs 1 for AGMB).
- GILD has more recent analyst coverage (25 ratings vs 5 for AGMB).
- Company
- AgomAb Therapeutics NV
- Gilead Sciences Inc.
- Price
- $12.68-2.95%
- $129.35-1.16%
- Market cap
- $616.1M
- $160.55B
- 1M return
- -0.90%
- +3.36%
- 1Y return
- -16.67%
- +14.46%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2026
- 1992
- News (4w)
- 1
- 6
- Recent ratings
- 5
- 25
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest AGMB
- B. Riley Securities initiated coverage on AgomAb Therapeutics NV with a new price target
- SEC Form 6-K filed by AgomAb Therapeutics NV
- Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
- H.C. Wainwright initiated coverage on AgomAb Therapeutics NV with a new price target
- SEC Form 6-K filed by AgomAb Therapeutics NV
- Agomab Announces Results of Annual General Meeting
- SEC Form SCHEDULE 13G filed by AgomAb Therapeutics NV
- SEC Form SCHEDULE 13G filed by AgomAb Therapeutics NV
- Agomab to Participate in Upcoming Conferences
- SEC Form SCHEDULE 13G filed by AgomAb Therapeutics NV
Latest GILD
- CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
- Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
- Gilead Sciences downgraded by Leerink Partners with a new price target
- Chief Financial Officer Dickinson Andrew D sold $389,777 worth of shares (3,000 units at $129.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 168,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $389,758 worth of shares (3,000 units at $129.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 121,234 units (SEC Form 4)
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors